Option Care Health, Inc. (NASDAQ:OPCH) Director Purchases $969,220.00 in Stock

Option Care Health, Inc. (NASDAQ:OPCH) Director Harry M. Jansen Kraemer, Jr. purchased 43,000 shares of Option Care Health stock in a transaction that occurred on Friday, November 8th. The stock was acquired at an average price of $22.54 per share, with a total value of $969,220.00. Following the transaction, the director now owns 326,334 shares in the company, valued at $7,355,568.36. The trade was a 15.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Option Care Health Stock Up 0.0 %

Option Care Health stock opened at $22.19 on Friday. The company has a market cap of $3.78 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.37 and a beta of 1.32. Option Care Health, Inc. has a 1-year low of $22.04 and a 1-year high of $34.63. The stock’s 50 day moving average price is $29.03 and its 200 day moving average price is $29.49. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. JMP Securities upped their target price on shares of Option Care Health from $36.00 to $37.00 and gave the company a “market outperform” rating in a report on Monday, September 30th. Jefferies Financial Group cut Option Care Health from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $38.00 to $26.00 in a research report on Thursday, October 31st. Bank of America lowered Option Care Health from a “buy” rating to a “neutral” rating and dropped their target price for the company from $43.00 to $29.00 in a report on Wednesday, October 30th. Truist Financial decreased their price target on Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, The Goldman Sachs Group cut shares of Option Care Health from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $38.00 to $27.00 in a research note on Monday, November 4th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.83.

Institutional Trading of Option Care Health

Several hedge funds and other institutional investors have recently made changes to their positions in OPCH. UMB Bank n.a. increased its holdings in Option Care Health by 937.5% in the third quarter. UMB Bank n.a. now owns 830 shares of the company’s stock valued at $26,000 after buying an additional 750 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Option Care Health by 110.6% in the 3rd quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock worth $28,000 after acquiring an additional 471 shares during the period. Whittier Trust Co. of Nevada Inc. increased its stake in Option Care Health by 3,362.8% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 1,489 shares of the company’s stock valued at $47,000 after purchasing an additional 1,446 shares in the last quarter. SageView Advisory Group LLC acquired a new position in Option Care Health during the first quarter worth $85,000. Finally, International Assets Investment Management LLC boosted its position in Option Care Health by 3,029.7% during the third quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock worth $91,000 after purchasing an additional 2,757 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.